| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by journal name.
Page 4: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 901 | 6 | 8 | 66 1962 BRITISH MEDICAL JOURNAL (5300):306-& YORKE RA; KILSHAW D; TAYLOR WH; SUTTON WS NEUROPATHY, HYPOGLYCAEMIA, AND ADRENAL DYSFUNCTION DURING TREATMENT WITH THALIDOMIDE | 0 | 0 |
| 902 | 0 | 0 | 67 1962 BRITISH MEDICAL JOURNAL (5303):522-& WHITEFRA.A THALIDOMIDE BABIES MEMORANDUM FROM BRITISH PAEDIATRIC ASSOCIATION | 0 | 0 |
| 903 | 0 | 0 | 68 1962 BRITISH MEDICAL JOURNAL (5303):545-& APPLEBEY M HELP FOR THALIDOMIDE BABIES | 0 | 0 |
| 904 | 3 | 6 | 69 1962 BRITISH MEDICAL JOURNAL (5305):646-& WARD SP THALIDOMIDE AND CONGENITAL ABNORMALITIES | 3 | 3 |
| 905 | 2 | 3 | 70 1962 BRITISH MEDICAL JOURNAL (5305):647-& GILLIS L THALIDOMIDE BABIES - MANAGEMENT OF LIMB DEFECTS | 0 | 0 |
| 906 | 0 | 6 | 71 1962 BRITISH MEDICAL JOURNAL (5305):672-& BASSIL GT; RIESS W; SCHMID K; KEBERLE H; FAIGLE JW THALIDOMIDE AND GLUTETHIMIDE | 0 | 0 |
| 907 | 0 | 0 | 72 1962 BRITISH MEDICAL JOURNAL (5305):673-& CAPENER N THALIDOMIDE BABIES | 0 | 0 |
| 908 | 0 | 0 | 73 1962 BRITISH MEDICAL JOURNAL (5307):785-& [Anon] PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 909 | 0 | 0 | 74 1962 BRITISH MEDICAL JOURNAL (5307):796-& SAUNDERS H; WRIGHT R; HODGKIN K THALIDOMIDE AND CONGENITAL DEFORMITIES | 0 | 0 |
| 910 | 0 | 0 | 75 1962 BRITISH MEDICAL JOURNAL (5308):857-& CLAY AA DEFORMITIES NOT DUE TO THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 911 | 0 | 0 | 76 1962 BRITISH MEDICAL JOURNAL (5309):920-& WOOLLAM DHM THALIDOMIDE AND MOUSE | 2 | 2 |
| 912 | 1 | 1 | 77 1962 BRITISH MEDICAL JOURNAL (5311):1061-& RICEEDWARDS TJ; BELL R THALIDOMIDE AND MOUSE | 0 | 0 |
| 913 | 0 | 2 | 78 1962 BRITISH MEDICAL JOURNAL (5313):1176-& [Anon] CENSUS OF THALIDOMIDE BABIES | 0 | 0 |
| 914 | 0 | 1 | 79 1962 BRITISH MEDICAL JOURNAL (5314):1257-& HEWITT HB THALIDOMIDE AND CANCER | 1 | 1 |
| 915 | 0 | 0 | 80 1962 BRITISH MEDICAL JOURNAL (5315):1321-& WOOLLAM DHM CENSUS OF THALIDOMIDE MOTHERS | 0 | 1 |
| 916 | 3 | 5 | 81 1962 BRITISH MEDICAL JOURNAL (5317):1447-& LECUTIER MA PHOCOMELIA AND INTERNAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
| 917 | 0 | 0 | 82 1962 BRITISH MEDICAL JOURNAL (5317):1462-& BURROWS HJ; RITCHIE T; WILSON K; SHARRARD WJ; CHAMBERLAIN R; SWETNAM; WIGGLESWORTH R; MCKENZIE DS; GILLIS L; JOLLY DW; WINNER A MANAGEMENT OF THALIDOMIDE DEFORMITIES | 0 | 0 |
| 918 | 2 | 2 | 83 1962 BRITISH MEDICAL JOURNAL (5317):1476-& RICEEDWARDS JT THALIDOMIDE AND CANCER | 0 | 0 |
| 919 | 11 | 34 | 84 1962 BRITISH MEDICAL JOURNAL 2(5296):14-& LECK IM; MILLAR ELM INCIDENCE OF MALFORMATIONS SINCE INTRODUCTION OF THALIDOMIDE | 25 | 64 |
| 920 | 0 | 0 | 194 1963 BRITISH MEDICAL JOURNAL (532):123-& STEWART A CONGENITAL DEFECTS DUE TO THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 921 | 0 | 0 | 195 1963 BRITISH MEDICAL JOURNAL (532):456-& [Anon] DERMATOGLYPHICS OF THALIDOMIDE BABIES | 0 | 0 |
| 922 | 2 | 19 | 196 1963 BRITISH MEDICAL JOURNAL (533):610-& EVERED DF; RANDAL HG THALIDOMIDE AND B VITAMINS | 0 | 0 |
| 923 | 0 | 1 | 197 1963 BRITISH MEDICAL JOURNAL (533):664-& [Anon] SEX RATIO OF THALIDOMIDE BABIES | 0 | 0 |
| 924 | 0 | 0 | 198 1963 BRITISH MEDICAL JOURNAL (534):1333-& [Anon] CONTINUING EFFECT OF THALIDOMIDE | 0 | 0 |
| 925 | 3 | 24 | 199 1963 BRITISH MEDICAL JOURNAL (536):973-& BUCKLE RM BLOOD PYRUVIC ACID IN THALIDOMIDE NEUROPATHY | 0 | 0 |
| 926 | 1 | 3 | 200 1963 BRITISH MEDICAL JOURNAL (537):1527-& SIMPSON JA THALIDOMIDE NEUROPATHY | 0 | 0 |
| 927 | 0 | 2 | 275 1964 BRITISH MEDICAL JOURNAL 1(539):1090-& LUTWAKMANN C OBSERVATIONS ON PROGENY OF THALIDOMIDE-TREATED MALE RABBITS | 8 | 36 |
| 928 | 0 | 1 | 276 1964 BRITISH MEDICAL JOURNAL 1(539):1559-& LUTWAKMANN C THALIDOMIDE-TREATED MALE RABBITS | 0 | 0 |
| 929 | 0 | 0 | 277 1964 BRITISH MEDICAL JOURNAL 2(541):679-& [Anon] ONCOLYTIC PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 930 | 5 | 12 | 320 1965 BRITISH MEDICAL JOURNAL 2(5463):687-& HELLMANN K; DUKE DI; TUCKER DF PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE | 49 | 73 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 931 | 1 | 3 | 321 1965 BRITISH MEDICAL JOURNAL 2(5469):1064-& JAMES WH TERATOGENETIC PROPERTIES OF THALIDOMIDE | 1 | 2 |
| 932 | 0 | 0 | 364 1966 BRITISH MEDICAL JOURNAL 1(5479):92-& [Anon] THALIDOMIDE NEUROPATHY | 0 | 0 |
| 933 | 1 | 1 | 365 1966 BRITISH MEDICAL JOURNAL 2(5510):400-& [Anon] THALIDOMIDE | 0 | 0 |
| 934 | 5 | 6 | 428 1967 BRITISH MEDICAL JOURNAL 4(5578):536-& [Anon] THALIDOMIDE IN LEPROSY | 0 | 0 |
| 935 | 2 | 6 | 454 1968 BRITISH MEDICAL JOURNAL 3(5609):42-& BERKELEY JS THALIDOMIDE IN LEPROSY | 1 | 1 |
| 936 | 0 | 0 | 455 1968 BRITISH MEDICAL JOURNAL 4(5624):190-& BELL R THALIDOMIDE | 0 | 0 |
| 937 | 0 | 2 | 517 1971 BRITISH MEDICAL JOURNAL 3(5767):186-& BELL R THALIDOMIDE | 0 | 0 |
| 938 | 1 | 1 | 563 1973 BRITISH MEDICAL JOURNAL 1(5848):269-272 SMITHELL.RW DEFECTS AND DISABILITIES OF THALIDOMIDE CHILDREN | 0 | 27 |
| 939 | 1 | 5 | 643 1977 BRITISH MEDICAL JOURNAL 2(6096):1191-1191 MURPHY R; MOHR P 2 CONGENITAL NEUROLOGICAL ABNORMALITIES CAUSED BY THALIDOMIDE | 2 | 2 |
| 940 | 2 | 8 | 644 1977 BRITISH MEDICAL JOURNAL 2(6103):1672-1672 PHELPS PD; ROLAND PE THALIDOMIDE AND CRANIAL NERVE ABNORMALITIES | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 941 | 1 | 2 | 665 1978 BRITISH MEDICAL JOURNAL 1(6107):237-237 GORDON GC THALIDOMIDE AND CRANIAL NERVE ABNORMALITIES | 0 | 0 |
| 942 | 1 | 4 | 692 1979 BRITISH MEDICAL JOURNAL 1(6166):792-792 WATERS MFR; LAING ABG; AMBIKAPATHY A; LENNARDJONES JE TREATMENT OF ULCERATIVE-COLITIS WITH THALIDOMIDE | 27 | 36 |
| 943 | 0 | 1 | 693 1979 BRITISH MEDICAL JOURNAL 1(6178):1625-1625 MUNRO I THALIDOMIDE AND THE LANCET | 0 | 0 |
| 944 | 0 | 2 | 694 1979 BRITISH MEDICAL JOURNAL 1(6180):1794-1795 ROE FJC THALIDOMIDE AND THE LANCET | 0 | 0 |
| 945 | 0 | 20 | 807 1983 BRITISH MEDICAL JOURNAL 286(6360):199-202 VENNING GR IDENTIFICATION OF ADVERSE REACTIONS TO NEW DRUGS .1. WHAT HAVE BEEN THE IMPORTANT ADVERSE REACTIONS SINCE THALIDOMIDE | 0 | 59 |
| 946 | 2 | 2 | 808 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
| 947 | 1 | 2 | 809 1983 BRITISH MEDICAL JOURNAL 287(6400):1225-1225 WALKER W; LEWIS HBM; ALBERTRECHT F EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 0 | 0 |
| 948 | 2 | 5 | 810 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 EFTHIMIOU J; SPIRO SG EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 2 | 2 |
| 949 | 0 | 0 | 811 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION - REPLY | 1 | 1 |
| 950 | 0 | 1 | 847 1984 BRITISH MEDICAL JOURNAL 289(6456):1424-1424 HASSAN EM; GOSSMAN HH THALIDOMIDE AND MULTIPLE CEREBRAL ANEURYSMS - FORTUITOUS OR CAUSAL ASSOCIATION | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 951 | 3 | 6 | 991 1989 BRITISH MEDICAL JOURNAL 298(6665):6-6 CHAMBERLAIN G THE OBSTETRIC PROBLEMS OF THE THALIDOMIDE CHILDREN | 0 | 0 |
| 952 | 4 | 5 | 992 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
| 953 | 4 | 8 | 1038 1991 BRITISH MEDICAL JOURNAL 302(6792):1603-1604 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 6 | 7 |
| 954 | 4 | 10 | 1039 1991 BRITISH MEDICAL JOURNAL 303(6800):470-470 WATERS MFR USE OF THALIDOMIDE IN LEPROSY | 5 | 5 |
| 955 | 5 | 10 | 1040 1991 BRITISH MEDICAL JOURNAL 303(6809):1062-1063 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| 956 | 2 | 11 | 1041 1991 BRITISH MEDICAL JOURNAL 303(6814):1404-1405 HOOPER M USE OF THALIDOMIDE IN LEPROSY | 2 | 2 |
| 957 | 0 | 0 | 1091 1993 BRITISH MEDICAL JOURNAL 307(6901):404-404 JOHN D DOCTOR WHO FOUND THALIDOMIDE DANGERS IS STRUCK OFF | 0 | 0 |
| 958 | 3 | 4 | 1092 1993 BRITISH MEDICAL JOURNAL 307(6909):939-940 BURROWS NP DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS - THALIDOMIDE MODIFIES DISEASE | 1 | 1 |
| 959 | 0 | 0 | 1125 1994 BRITISH MEDICAL JOURNAL 308(6931):739-739 CHRISTIE B THALIDOMIDE VICTIMS WIN REVIEW OF COMPENSATION | 2 | 2 |
| 960 | 0 | 0 | 1126 1994 BRITISH MEDICAL JOURNAL 308(6936):1061-1061 ROCHA J THALIDOMIDE GIVEN TO WOMEN IN BRAZIL | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 961 | 5 | 5 | 1127 1994 BRITISH MEDICAL JOURNAL 308(6941):1437-1438 CRAWFORD CL SAFETY OF THALIDOMIDE | 4 | 4 |
| 962 | 3 | 4 | 1128 1994 BRITISH MEDICAL JOURNAL 308(6944):1635-1636 MCBRIDE WG THALIDOMIDE MAY BE A MUTAGEN | 16 | 22 |
| 963 | 0 | 3 | 1129 1994 BRITISH MEDICAL JOURNAL 308(6944):1636-1636 READ AP THALIDOMIDE MAY BE A MUTAGEN - COMMENT | 11 | 13 |
| 964 | 1 | 3 | 1130 1994 BRITISH MEDICAL JOURNAL 309(6948):193-194 ASSCHER W SAFETY OF THALIDOMIDE | 2 | 2 |
| 965 | 2 | 2 | 1131 1994 BRITISH MEDICAL JOURNAL 309(6952):477-477 SMITHELLS RW THALIDOMIDE MAY BE A MUTAGEN | 8 | 9 |
| 966 | 1 | 1 | 1132 1994 BRITISH MEDICAL JOURNAL 309(6956):741-741 KIDA M THALIDOMIDE MAY NOT BE A MUTAGEN | 5 | 7 |
| 967 | 3 | 5 | 1133 1994 BRITISH MEDICAL JOURNAL 309(6966):1442-1442 TENCONI R; CLEMENTI M; NOTARI L; VASCO VRLO AMNIOTIC BAND SEQUENCE IN CHILD OF THALIDOMIDE VICTIM | 4 | 6 |
| 968 | 9 | 11 | 1250 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
| 969 | 0 | 0 | 1320 1997 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
| 970 | 2 | 3 | 1421 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 971 | 5 | 5 | 2146 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
| 972 | 0 | 1 | 2424 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
| 973 | 5 | 45 | 456 1968 BULLETIN DU CANCER 55(3):413-& BAROCHE C ACTIONS OF THALIDOMIDE ON DROSOPHILA WITH REGARD TO DEVELOPMENT AND TUMORIGENESIS - COMPARISONS WITH EFFECT OF POTASSIUM PHTHALATE AND SOME NON-PHTHALATE COMPOUNDS | 1 | 1 |
| 974 | 6 | 18 | 812 1983 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE 96(7):910-913 VAISMAN BL; POPOV VP; IGNATEVA TV REDUCTION IN THE TISSUE ASCORBIC-ACID LEVEL IN GUINEA-PIGS BY THALIDOMIDE | 1 | 2 |
| 975 | 14 | 28 | 366 1966 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE,USSR 61(2):185-& ALEKSAND.PN; BOGDANOV.VA; CHERNUKH AM TERATOGENIC EFFECT OF THALIDOMIDE IN EXPERIMENTS ON CHICK EMBRYOS | 0 | 0 |
| 976 | 5 | 5 | 278 1964 BULLETIN OF THE JOHNS HOPKINS HOSPITAL 115(3):223-& DEKKER A; MEHRIZI A USE OF THALIDOMIDE AS TERATOGENIC AGENT IN RABBITS | 9 | 15 |
| 977 | 3 | 14 | 518 1971 BULLETIN OF THE WORLD HEALTH ORGANIZATION 45(6):719-& IYER CGS; LANGUILL.J; UEMURA K; TARABINI.G; SUNDARES.T; BECHELLI LM; DOMINGUE.VM; DELASAGU.JT; RAMANUJA.K WHO COORDINATED SHORT-TERM DOUBLE-BLIND TRIAL WITH THALIDOMIDE IN TREATMENT OF ACUTE LEPRA REACTIONS IN MALE LEPROMATOUS PATIENTS | 62 | 72 |
| 978 | 0 | 0 | 1687 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 979 | 5 | 19 | 457 1968 CANADIAN JOURNAL OF ANIMAL SCIENCE 48(3):285-& KONDRA PA; SELL JL; MCKIRDY JA EFFECT OF THALIDOMIDE ON EMBRYONIC AND POST-EMBRYONIC DEVELOPMENT OF CHICK | 0 | 0 |
| 980 | 4 | 25 | 322 1965 CANADIAN JOURNAL OF BIOCHEMISTRY 43(6):769-& KIM HC; PAIK WK; DIORIO A EFFECT OF THALIDOMIDE AND ITS DERIVATIVES ON THYROXINE-INDUCED METAMORPHOSIS OF TADPOLE | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 981 | 11 | 24 | 279 1964 CANADIAN JOURNAL OF BIOCHEMISTRY AND PHYSIOLOGY 42(1):35-& BOYLEN JB; HORNE HH; JOHNSON WJ TERATOGENIC EFFECTS OF THALIDOMIDE + ITS METABOLITES ON DEVELOPING CHICK EMBRYO | 12 | 17 |
| 982 | 1 | 5 | 201 1963 CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE 41(7):1722-& MENARD M; ERICHOMO.L; LABROOY M; CHUBB FL QUELQUES METABOLITES POSSIBLES DE LA THALIDOMIDE | 3 | 8 |
| 983 | 15 | 15 | 2602 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(2):101-104 Hershfield NB Disappearance of Chron's ulcers in the terminal ileum after thalidomide therapy | 0 | 0 |
| 984 | 2 | 3 | 2603 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Cohen LB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. | 0 | 0 |
| 985 | 0 | 0 | 2604 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Hershfield NB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Response | 0 | 0 |
| 986 | 7 | 10 | 367 1966 CANADIAN JOURNAL OF MICROBIOLOGY 12(2):333-& JASMIN R; JOHNSON WJ RENVERSEMENT PAR LA THIAMINE ET LE PYRIDOXAL DE LINHIBITION PRODUITE PAR LHYDROXY-3 THALIDOMIDE SUR LA CROISSANCE DESCHERICHIA COLI | 1 | 1 |
| 987 | 2 | 6 | 721 1980 CANADIAN JOURNAL OF PHARMACEUTICAL SCIENCES 15(2):21-23 JACKSON AJ; SCHUMACHER HJ IDENTIFICATION OF URINARY METABOLITES OF EM12 N-(2',6'- DIOXOPIPERIDEN-3'-YL)-PHTHALIMIDINE, A TERATOGENIC ANALOG OF THALIDOMIDE IN RATS AND RABBITS | 7 | 7 |
| 988 | 10 | 22 | 323 1965 CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 43(1):69-& MCCOLL JD; GLOBUS M; ROBINSON S AN ATTEMPTED REVERSAL OF THALIDOMIDE EMBRYOPATHY IN RAT BY GLUTAMINE | 7 | 10 |
| 989 | 9 | 13 | 85 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(10):462-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 990 | 0 | 0 | 86 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(14):664-& [Anon] WITHDRAWAL OF THALIDOMIDE FROM MARKET | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 991 | 0 | 0 | 87 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(14):665-& MUNN JD THALIDOMIDE AND CONGENITAL MALFORMATIONS | 2 | 2 |
| 992 | 3 | 7 | 88 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(16):744-& RODIN AE; KOLLER LA; TAYLOR JD ASSOCIATION OF THALIDOMIDE (KEVADON) WITH CONGENITAL ANOMALIES | 8 | 13 |
| 993 | 0 | 0 | 89 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(8):412-& [Anon] DISPOSAL OF SUPPLIES OF THALIDOMIDE | 0 | 0 |
| 994 | 3 | 6 | 90 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(12):670-& IVES EJ THALIDOMIDE AND ANAL ABNORMALITIES | 1 | 8 |
| 995 | 0 | 0 | 91 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(18):981-& THEORET JJ CHRONOLOGY OF THALIDOMIDE STORY | 0 | 0 |
| 996 | 8 | 14 | 92 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(24):1259-& LING GM; DOLMAN CL; BOYD JR DRUG-INDUCED (THALIDOMIDE) MALFORMATIONS | 6 | 7 |
| 997 | 0 | 0 | 93 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(24):1293-& GILDER SSB THALIDOMIDE AND AFTER | 0 | 0 |
| 998 | 0 | 0 | 202 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(2):99-& JONG JDD THALIDOMIDE AND FUTURE CONTROL OF DRUGS | 0 | 0 |
| 999 | 0 | 0 | 203 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(9):488-& [Anon] REHABILITATION OF THALIDOMIDE-DEFORMED CHILDREN | 0 | 0 |
| 1000 | 7 | 9 | 204 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):959-& MARTIN JK; RATHBUN JC HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - PEDIATRIC ASPECTS | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1001 | 0 | 0 | 205 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):962-& LAZURE D HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - PSYCHIATRIC AND PSYCHOLOGICAL ASPECTS | 1 | 1 |
| 1002 | 0 | 10 | 206 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):964-& HALL JE HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - SURGERY OF LIMB DEFECTS | 3 | 3 |
| 1003 | 0 | 2 | 207 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):973-& GILPIN RE HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - PROSTHETIC ASPECTS | 3 | 3 |
| 1004 | 0 | 0 | 208 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):980-& ARMSTRONG KS HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - MEDICAL-SOCIAL ASPECTS | 1 | 1 |
| 1005 | 0 | 2 | 209 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 89(3):141-& GILDER SSB ECHOES OF THALIDOMIDE | 0 | 0 |
| 1006 | 10 | 16 | 210 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 89(19):987-& WEBB JF CANADIAN THALIDOMIDE EXPERIENCE | 0 | 5 |
| 1007 | 1 | 8 | 324 1965 CANADIAN MEDICAL ASSOCIATION JOURNAL 92(6):283-& HAGEN EO CONGENITAL MALFORMATIONS IN A THALIDOMIDE BABY - A POSTMORTEM ANATOMICAL STUDY | 3 | 4 |
| 1008 | 0 | 0 | 325 1965 CANADIAN MEDICAL ASSOCIATION JOURNAL 92(11):585-& WEBB JF THALIDOMIDE PROBLEM IN CANADA | 0 | 0 |
| 1009 | 0 | 2 | 368 1966 CANADIAN MEDICAL ASSOCIATION JOURNAL 95(6):280-& GILDER SSB LONDON LETTER - LIVING OR DEAD - TREATMENT OF ACUTE LEUKEMIA IN ADULTS - THALIDOMIDE AND IMMUNOLOGY - DESCENDING PERINEUM - LOW INTELLIGENCE AND OBSTETERIC COMPLICATIONS | 0 | 0 |
| 1010 | 13 | 20 | 369 1966 CANADIAN MEDICAL ASSOCIATION JOURNAL 95(9):390-& MONGEAU M; GINGRAS G; SHERMAN ED; HEBERT B; HUTCHISO.J; CORRIVEA.C MEDICAL AND PSYCHOSOCIAL ASPECTS OF HABILITATION OF THALIDOMIDE CHILDREN | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1011 | 0 | 0 | 481 1969 CANADIAN MEDICAL ASSOCIATION JOURNAL 100(17):827-& GILDER SSB THALIDOMIDE NEUROPATHY | 0 | 0 |
| 1012 | 1 | 8 | 499 1970 CANADIAN MEDICAL ASSOCIATION JOURNAL 103(2):163-& HUSAIN SM; BELANGER.M; PELLERIN M MALFORMATION IN PROGENY OF THALIDOMIDE-TREATED MALE RATS | 0 | 0 |
| 1013 | 0 | 0 | 645 1977 CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE 18(5):135-136 BUTLER H EFFECT OF THALIDOMIDE ON NONHUMAN-PRIMATES | 0 | 0 |
| 1014 | 32 | 67 | 1896 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 6 | 13 |
| 1015 | 13 | 33 | 2147 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 5 | 10 |
| 1016 | 6 | 43 | 2148 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 14 |
| 1017 | 5 | 34 | 2425 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 1 | 5 |
| 1018 | 7 | 8 | 2605 2004 CANCER 100(6):1186-1189 Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F Thalidomide for patients with recurrent lymphoma | 0 | 0 |
| 1019 | 17 | 29 | 2149 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
| 1020 | 24 | 35 | 1523 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1021 | 24 | 45 | 1688 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 20 |
| 1022 | 8 | 37 | 1897 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 9 |
| 1023 | 11 | 31 | 1898 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
| 1024 | 11 | 23 | 2150 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 1 | 1 |
| 1025 | 5 | 27 | 2426 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 1026 | 13 | 28 | 2606 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 1 | 1 |
| 1027 | 5 | 11 | 211 1963 CANCER CHEMOTHERAPY REPORTS (29):99-102 DIPAOLO JA EFFECT OF THALIDOMIDE ON A VARIETY OF TRANSPLANTABLE TUMORS | 0 | 3 |
| 1028 | 0 | 0 | 2427 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
| 1029 | 94 | 118 | 2151 2002 CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
| 1030 | 19 | 51 | 2152 2002 CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1031 | 15 | 23 | 1042 1991 CANCER LETTERS 60(2):129-133 GERSHBEIN LL THE THALIDOMIDE ANALOG, EM-12, ENHANCES 1,2-DIMETHYLHYDRAZINE-INDUCTION OF RAT COLON ADENOCARCINOMAS | 2 | 6 |
| 1032 | 4 | 17 | 1251 1996 CANCER LETTERS 101(1):21-24 Pollard M Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats | 8 | 12 |
| 1033 | 10 | 51 | 1899 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
| 1034 | 6 | 16 | 1689 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 1035 | 2 | 18 | 370 1966 CANCER RESEARCH 26(9P1):1884-& CHAUDHRY AP; SCHMUTZ JA EFFECTS OF PREDNISOLONE AND THALIDOMIDE ON INDUCED SUBMANDIBULAR GLAND TUMORS IN HAMSTERS | 0 | 1 |
| 1036 | 22 | 28 | 2428 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 6 | 13 |
| 1037 | 21 | 31 | 2429 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 3 | 5 |
| 1038 | 22 | 98 | 1690 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
| 1039 | 10 | 33 | 2607 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| 1040 | 4 | 5 | 2153 2002 CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418 Jin SH; Il Kim T; Han DS; Shin SK; Kim WH Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1041 | 11 | 51 | 1524 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 5 |
| 1042 | 39 | 60 | 1900 2001 CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
| 1043 | 5 | 39 | 2430 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
| 1044 | 0 | 0 | 813 1983 CHELSEA (42-4):237-237 RIDLAND J THE 'THALIDOMIDE KIDS ON TELEVISION (1978)' | 0 | 0 |
| 1045 | 0 | 0 | 564 1973 CHEMICAL & ENGINEERING NEWS 51(4):11-12 [Anon] STIFFER DRUG LAWS IN WAKE OF THALIDOMIDE | 0 | 0 |
| 1046 | 0 | 1 | 1093 1993 CHEMICAL & ENGINEERING NEWS 71(28):5-5 BAUM R THALIDOMIDE BLOCKS VIRUS THAT CAUSES AIDS | 0 | 0 |
| 1047 | 0 | 0 | 2154 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
| 1048 | 4 | 7 | 326 1965 CHEMICAL & PHARMACEUTICAL BULLETIN 13(10):1263-& TANAKA A; HASEGAWA A; URAKUBO G METABOLIC FATE OF THALIDOMIDE IN RATS | 6 | 7 |
| 1049 | 8 | 16 | 458 1968 CHEMICAL & PHARMACEUTICAL BULLETIN 16(11):2289-& MOHRI T; KITAGAWA H NEGATIVE EFFECT OF THALIDOMIDE AND RELATIVE SUBSTANCES ON GROWTH OF HELA CELLS | 0 | 1 |
| 1050 | 9 | 31 | 2431 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1051 | 6 | 23 | 2608 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 1052 | 3 | 18 | 2155 2002 CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
| 1053 | 18 | 41 | 1422 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
| 1054 | 2 | 11 | 722 1980 CHEMISCHE BERICHTE-RECUEIL 113(6):2318-2322 BLASCHKE G; KRAFT HP; MARKGRAF H CHROMATOGRAPHIC RESOLUTIONS OF RACEMATES .10. OPTICAL RESOLUTION OF THALIDOMIDE AND OTHER GLUTARIMIDE DERIVATIVES | 7 | 31 |
| 1055 | 4 | 12 | 327 1965 CHEMISTRY & INDUSTRY (24):1030-& SHEALY YF; OPLIGER CE; MONTGOME.JA D-AND 6-THALIDOMIDE | 0 | 16 |
| 1056 | 0 | 0 | 1321 1997 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
| 1057 | 0 | 0 | 1423 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
| 1058 | 0 | 0 | 1691 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| 1059 | 0 | 0 | 1134 1994 CHEMISTRY IN BRITAIN 30(4):280-280 CAREY J THALIDOMIDE DEBATE - REPLY | 0 | 0 |
| 1060 | 0 | 0 | 1135 1994 CHEMISTRY IN BRITAIN 30(4):280-280 HUNT JR THALIDOMIDE DEBATE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1061 | 0 | 0 | 1180 1995 CHEMISTRY IN BRITAIN 31(10):760-760 [Anon] THALIDOMIDE REVIVAL | 0 | 0 |
| 1062 | 1 | 2 | 1901 2001 CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| 1063 | 14 | 21 | 1322 1997 CHEMTECH 27(1):21-25 Muller GW Thalidomide: From tragedy to new drug discovery | 4 | 9 |
| 1064 | 15 | 29 | 2156 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 24 |
| 1065 | 3 | 10 | 1902 2001 CHILDS NERVOUS SYSTEM 17(6):370-372 Schoeman JF; Ravenscroft A; Hartzenberg HB Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess | 5 | 5 |
| 1066 | 0 | 12 | 1136 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
| 1067 | 19 | 25 | 1181 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 56 | 79 |
| 1068 | 13 | 28 | 1252 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
| 1069 | 15 | 22 | 1253 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 27 | 33 |
| 1070 | 13 | 23 | 1424 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1071 | 5 | 17 | 2609 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
| 1072 | 5 | 15 | 1692 2000 CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
| 1073 | 0 | 0 | 94 1962 CIRCULATION 26(4):795-& TAUSSIG HB THALIDOMIDE AND PHOCOMELIA | 0 | 0 |
| 1074 | 0 | 0 | 1425 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 1075 | 0 | 0 | 1903 2001 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |
| 1076 | 0 | 0 | 1904 2001 CIRCULATION 104(17):566-566 Kishan CV; Saucedo JF; Fahdi I; Gaddam V; Razek H; Bissett JK; Anaissie E; Barlogie B; Mehta JL High dose thalidomide is associated with symptomatic bradycardia | 0 | 0 |
| 1077 | 0 | 0 | 2432 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
| 1078 | 13 | 16 | 1525 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
| 1079 | 1 | 5 | 814 1983 CLINICAL AND EXPERIMENTAL DERMATOLOGY 8(2):208-209 LAURET P THALIDOMIDE AND THE MANAGEMENT OF LUPUS-ERYTHEMATOSUS | 0 | 1 |
| 1080 | 5 | 17 | 966 1988 CLINICAL AND EXPERIMENTAL DERMATOLOGY 13(6):408-410 MUNRO CS; COX NH PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCETS SYNDROME - RESPONSE TO THALIDOMIDE | 12 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1081 | 3 | 3 | 1094 1993 CLINICAL AND EXPERIMENTAL DERMATOLOGY 18(5):487-487 MISERY L; LARBRE B; LYONNET S; FAURE M; THIVOLET J REMISSION OF LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE TREATMENT | 11 | 18 |
| 1082 | 5 | 6 | 1182 1995 CLINICAL AND EXPERIMENTAL DERMATOLOGY 20(1):85-85 MISERY L; PEGUETNAVARRO J; THIVOLET J; FAURE M; SCHMITT D; CLAUDY AL THALIDOMIDE DOES NOT AFFECT IN-VITRO MIXED SKIN CELL LYMPHOCYTE REACTIONS | 0 | 1 |
| 1083 | 3 | 9 | 1323 1997 CLINICAL AND EXPERIMENTAL DERMATOLOGY 22(6):297-299 Darvay A; Basarab T; Russell-Jones R Thalidomide-induced toxic pustuloderma | 4 | 8 |
| 1084 | 9 | 10 | 1426 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
| 1085 | 6 | 10 | 1427 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
| 1086 | 2 | 13 | 2610 2004 CLINICAL AND EXPERIMENTAL DERMATOLOGY 29(3):268-270 Eisman S; Orteu CH Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment | 0 | 0 |
| 1087 | 5 | 22 | 500 1970 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 7(2):241-& COULSON AS; SUMMERS LJ; LINDAHLK.K; TUCKER D; HELLMANN K EFFECT OF 2 SOLUBLE THALIDOMIDE DERIVATIVES ON LYMPHOCYTE STIMULATION | 16 | 17 |
| 1088 | 15 | 34 | 1183 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 106 | 143 |
| 1089 | 6 | 22 | 1324 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 108(3):428-431 Hauschild A; Kroeger H; Mitchison NA; Ugrinovic S; Zwingenberger K Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift | 6 | 12 |
| 1090 | 31 | 50 | 1325 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1091 | 10 | 31 | 1526 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 1092 | 8 | 33 | 1693 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
| 1093 | 13 | 49 | 1694 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
| 1094 | 33 | 37 | 2157 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 15 | 17 |
| 1095 | 1 | 7 | 1007 1990 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 8(4):427-427 HAMZA M BEHCETS-DISEASE, PALMOPLANTAR PUSTULOSIS AND HLA-B27 TREATMENT WITH THALIDOMIDE | 8 | 9 |
| 1096 | 21 | 33 | 1095 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 46 | 64 |
| 1097 | 4 | 5 | 1527 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 1098 | 3 | 3 | 1905 2001 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 19(3):360-361 Scoville CD Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis | 5 | 5 |
| 1099 | 8 | 16 | 2158 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44 Seyahi E; Ozdogan H; Masatlioglu S; Yazici H Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient | 0 | 4 |
| 1100 | 90 | 130 | 2159 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1101 | 14 | 18 | 2160 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
| 1102 | 4 | 12 | 2433 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
| 1103 | 8 | 10 | 1184 1995 CLINICAL BIOCHEMISTRY 28(4):467-470 LYON AW; DURAN G; RAISYS VA DETERMINATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - METHODOLOGICAL STRATEGY FOR CLINICAL-TRIALS | 6 | 7 |
| 1104 | 0 | 0 | 1695 2000 CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 1105 | 8 | 17 | 1906 2001 CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 23 | 58 |
| 1106 | 13 | 35 | 1907 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 1107 | 8 | 25 | 1908 2001 CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 1 | 10 |
| 1108 | 12 | 56 | 1909 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 19 | 29 |
| 1109 | 0 | 0 | 1910 2001 CLINICAL CANCER RESEARCH 7(11):3666S-3667S Hsu C; Chen C; Chen L; Wu C; Hsieh F; Cheng A Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response. | 0 | 0 |
| 1110 | 28 | 54 | 2161 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 13 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1111 | 1 | 9 | 2162 2002 CLINICAL CANCER RESEARCH 8(8):2750-2750 Go RS; Horstman AL Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. | 0 | 0 |
| 1112 | 0 | 6 | 2163 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
| 1113 | 17 | 24 | 2164 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
| 1114 | 30 | 38 | 2434 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 5 | 6 |
| 1115 | 0 | 0 | 2435 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
| 1116 | 8 | 8 | 2436 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
| 1117 | 0 | 0 | 2437 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
| 1118 | 10 | 20 | 2611 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
| 1119 | 6 | 6 | 1185 1995 CLINICAL CHEMISTRY 41(8):1199-1199 HUUPPONEN R; PYYKKO K STABILITY OF THALIDOMIDE IN HUMAN PLASMA | 6 | 8 |
| 1120 | 5 | 5 | 1326 1997 CLINICAL CHEMISTRY 43(6):1094-1095 Eriksson T; Bjorkman S Handling of blood samples for determination of thalidomide | 6 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1121 | 4 | 5 | 1327 1997 CLINICAL CHEMISTRY 43(6):1095-1096 Lyon AW; Raisys VA Handling of blood samples for determination of thalidomide - Respond | 0 | 0 |
| 1122 | 13 | 49 | 1696 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
| 1123 | 12 | 49 | 2165 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 7 |
| 1124 | 0 | 0 | 2166 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
| 1125 | 10 | 36 | 1254 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 39 | 56 |
| 1126 | 27 | 38 | 1186 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
| 1127 | 5 | 13 | 1255 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
| 1128 | 2 | 12 | 1256 1996 CLINICAL INFECTIOUS DISEASES 23(3):504-505 Levine AM Editorial response - Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 1 | 1 |
| 1129 | 13 | 25 | 1328 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| 1130 | 2 | 5 | 1428 1998 CLINICAL INFECTIOUS DISEASES 26(1):184-185 Gori A; Franzetti F; Marchetti G; Rossi C; Fusi ML; Ruzzante S; Clerici M Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection | 5 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1131 | 4 | 10 | 1528 1999 CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
| 1132 | 12 | 33 | 1697 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
| 1133 | 0 | 0 | 1698 2000 CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| 1134 | 0 | 0 | 1911 2001 CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
| 1135 | 16 | 25 | 2438 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 4 | 8 |
| 1136 | 9 | 21 | 2439 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
| 1137 | 5 | 20 | 2440 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 1 | 4 |
| 1138 | 3 | 23 | 2612 2004 CLINICAL NEPHROLOGY 61(5):352-356 Menegato MA; Canelles MF; Tonutti E; Pizzolitto S Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease | 0 | 0 |
| 1139 | 19 | 42 | 1329 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
| 1140 | 6 | 11 | 1529 1999 CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1141 | 0 | 4 | 723 1980 CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (148):18-25 FLETCHER I REVIEW OF THE TREATMENT OF THALIDOMIDE CHILDREN WITH LIMB DEFICIENCY IN GREAT-BRITAIN | 0 | 0 |
| 1142 | 0 | 0 | 371 1966 CLINICAL PEDIATRICS 5(4):255-& SMITHELL.RW THALIDOMIDE SYNDROME - COMPREHENSIVE CARE | 0 | 1 |
| 1143 | 52 | 65 | 2613 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 0 | 0 |
| 1144 | 8 | 14 | 328 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):292-& OLSON KB; HALL TC; HORTON J; KHUNG CL; HOSLEY HF THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN TREATMENT OF ADVANCED CANCER | 22 | 26 |
| 1145 | 6 | 17 | 329 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):298-& GRABSTAL.H; GOLBEY R CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER | 0 | 27 |
| 1146 | 0 | 0 | 330 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):303-& SHESKIN J THALIDOMIDE IN TREATMENT OF LEPRA REACTIONS | 215 | 259 |
| 1147 | 8 | 22 | 501 1970 CLINICAL PHARMACOLOGY & THERAPEUTICS 11(4):481-& HASTINGS RC; TRAUTMAN JR; ENNA CD; JACOBSON RR THALIDOMIDE IN TREATMENT OF ERYTHEMA NODOSUM LEPROSUM - WITH A NOTE ON SELECTED LABORATORY ABNORMALITIES IN ERYTHEMA NODOSUM LEPROSUM | 30 | 40 |
| 1148 | 0 | 0 | 565 1973 CLINICAL PHARMACOLOGY & THERAPEUTICS 14(4):660-661 STERN L LESSON OF THALIDOMIDE | 0 | 2 |
| 1149 | 0 | 0 | 1330 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PI44-PI44 OToole EA; Nasca MR; Palicharla P; West DP; Woodley DT Thalidomide increases keratinocyte proliferation and chemokine secretion in vitro | 0 | 0 |
| 1150 | 0 | 0 | 1331 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PIV89-PIV89 Donahue SR; Collins JM; Flockhart DA; Abernethy DR; Trapnell CB Thalidomide pharmacokinetics do not change with chronic administration | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1151 | 9 | 27 | 1429 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 1152 | 9 | 27 | 1530 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 1153 | 0 | 0 | 1699 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 1154 | 0 | 0 | 2167 2002 CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
| 1155 | 0 | 0 | 2441 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
| 1156 | 0 | 1 | 1531 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 1157 | 0 | 0 | 815 1983 CLINICAL RESEARCH 31(2):A266-A266 MONCADA B; BARANDA ML; LOREDO C; URBINA R; GONZALEZAMARO R; HERNANDEZRODRIGUEZ H THALIDOMIDE AND LEPRA REACTION - DOES THE DRUG AFFECT LYMPHOCYTE POPULATIONS | 0 | 0 |
| 1158 | 0 | 0 | 816 1983 CLINICAL RESEARCH 31(5):A920-A920 DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE; MILLIKAN LE THALIDOMIDE INDUCED ALTERATION OF HUMAN PERIPHERAL-BLOOD MONOCYTE ACTIVITY | 3 | 3 |
| 1159 | 0 | 0 | 817 1983 CLINICAL RESEARCH 31(5):A921-A921 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 1 | 1 |
| 1160 | 0 | 0 | 848 1984 CLINICAL RESEARCH 32(2):A569-A569 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1161 | 0 | 0 | 849 1984 CLINICAL RESEARCH 32(2):A603-A603 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 0 | 0 |
| 1162 | 0 | 0 | 1096 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
| 1163 | 0 | 0 | 1137 1994 CLINICAL RESEARCH 42(2):A142-A142 RIFKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM INDUCTION OF TH2, AND INHIBITION OF TH1, LYMPHOCYTE-RESPONSES BY THALIDOMIDE | 0 | 0 |
| 1164 | 0 | 0 | 917 1986 CLINICAL RHEUMATOLOGY 5(3):365-371 HAMZA MH TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 21 | 39 |
| 1165 | 0 | 0 | 942 1987 CLINICAL RHEUMATOLOGY 6(4):608-609 HAMZA M; HAMZAOUI K; AYED K; ELEUCH M; ZRIBI A THALIDOMIDE AND CELL-MEDIATED IMMUNITY IN BEHCETS-DISEASE | 0 | 2 |
| 1166 | 6 | 17 | 1532 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 37 | 45 |
| 1167 | 166 | 221 | 2442 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 5 |
| 1168 | 53 | 221 | 1700 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 1169 | 11 | 35 | 918 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
| 1170 | 0 | 0 | 212 1963 COLUMBIA JOURNALISM REVIEW 1(4):53-53 SILBER F MORE ON THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1171 | 0 | 1 | 695 1979 COLUMBIA JOURNALISM REVIEW 18(2):74-74 BALK A SUFFER THE CHILDREN - STORY OF THALIDOMIDE | 0 | 0 |
| 1172 | 1 | 236 | 1332 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
| 1173 | 0 | 5 | 95 1962 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 156(5):765-& GIROUD A; MERCIERPAROT L; TUCHMANNDUPLESS.H OBSERVATIONS SUR LES REPERCUSSIONS TERATOGENES DE LA THALIDOMIDE CHEZ LA SOURIS ET LE LAPIN | 14 | 38 |
| 1174 | 0 | 9 | 280 1964 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 158(4):737-& BERTRAND M; FLORIO R; DELATOUR P; MAGAT A SUR LA POTENTIALISATION DES EFFETS EMBRYOTOXIQUES DU THALIDOMIDE CHEZ LA RATTE | 2 | 3 |
| 1175 | 3 | 5 | 331 1965 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 159(5):1059-& CAHEN CRR; DUPUIS R MALFORMATIONS VISCERALES PROVOQUEES PAR LE THALIDOMIDE CHEZ LE LAPIN | 0 | 0 |
| 1176 | 1 | 3 | 96 1962 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 255(14):1646-& GIROUD A; MERCIERPAROT L; TUCHMANNDUPLESSIS H EMBRYOLOGIE TERATOLOGIQUE - PRODUCTION DE MALFORMATIONS CONGENITALES CHEZ LA SOURIS APRES ADMINISTRATION DE FAIBLES DOSES DE THALIDOMIDE | 2 | 13 |
| 1177 | 2 | 3 | 213 1963 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 256(12):2719-& SALZGEBER B; SALAUN J TERATOGENESE EXPERIMENTALE - MALFORMATIONS DE MEMBRES OBTENUES CHEZ LEMBRYON DE POULET APRES TRAITEMENT PAR LA THALIDOMIDE | 8 | 14 |
| 1178 | 2 | 4 | 214 1963 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 257(1):273-& SALZGEBER B; SALAUN J TERATOLOGIE EXPERIMENTALE - ACTION TERATOGENE DE LA THALIDOMIDE SUR LEMBRYON DE POULET, A DIFFERENTS STADES DU DEVELOPPEMENT | 2 | 5 |
| 1179 | 0 | 5 | 215 1963 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 257(21):3138-& CHAMPYHATEM S SPECTROSCOPIE MOLECULAIRE - SUR LABSORPTION ULTRAVIOLETTE DU PHTALIMIDE ET DE LA THALIDOMIDE EN MILIEU ALCALIN | 3 | 6 |
| 1180 | 0 | 3 | 332 1965 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 260(15):4208-& CHAMPYHA.S IMIDAZOLE ET THALIDOMIDE . ETUDE SPECTRALE COMPAREE DES DEUX NOYAUX PHTALIMIDE ET GLUTARIMIDE | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1181 | 0 | 6 | 333 1965 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 261(1):271-& CHAMPYHA.S LE GLUTARIMIDE ET LACTIVITE DE LA THALIDOMIDE . ETUDE SPECTRALE ETENDUE JUSQUE VERS 2050 A | 0 | 9 |
| 1182 | 0 | 1 | 724 1980 CONTEMPORARY SOCIOLOGY-A JOURNAL OF REVIEWS 9(3):354-358 JACKALL R SUFFER THE CHILDREN - THE STORY OF THALIDOMIDE - INSIGHT-TEAM-OF-THE-SUNDAY-TIMES-OF-LONDON | 0 | 0 |
| 1183 | 61 | 82 | 2168 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| 1184 | 52 | 86 | 2443 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 0 | 1 |
| 1185 | 13 | 38 | 2444 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 1186 | 61 | 107 | 2169 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
| 1187 | 6 | 33 | 919 1986 CURRENT CONTENTS (50):3-11 GARFIELD E TERATOLOGY LITERATURE AND THE THALIDOMIDE CONTROVERSY | 0 | 0 |
| 1188 | 3 | 44 | 1533 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 1189 | 26 | 80 | 1430 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 14 | 36 |
| 1190 | 44 | 59 | 2445 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1191 | 49 | 95 | 1701 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 40 |
| 1192 | 28 | 123 | 1912 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
| 1193 | 33 | 53 | 2170 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 5 | 10 |
| 1194 | 1 | 2 | 429 1967 CURRENT SCIENCE 36(20):556-& SINGH D; JOSHI BC CHROMOSOME BREAKAGE INDUCED BY HYDROLYTIC PRODUCTS OF THALIDOMIDE IN VICIA FABA | 0 | 0 |
| 1195 | 5 | 9 | 372 1966 CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL 8(6):299-& CAZORT RJ; SONG YK A TRIAL OF THALIDOMIDE IN PROGRESSIVE LEPRA REACTIONS | 9 | 11 |
| 1196 | 10 | 29 | 2614 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 1197 | 100 | 115 | 1913 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
| 1198 | 0 | 1 | 373 1966 DERMATOLOGICA 133(5):433-& HOGERZEI.LM; SIMONS RDG THALIDOMIDE-THERAPY IN ACUTE LEPROSY REACTIONS | 0 | 0 |
| 1199 | 1 | 5 | 747 1981 DERMATOLOGICA 162(2):86-90 SHESKIN J; GORODETZKY R; LOEWINGER E; WEINREB A INVIVO MEASUREMENTS OF IRON, COPPER AND ZINC IN THE SKIN OF PRURIGO NODULARIS PATIENTS TREATED WITH THALIDOMIDE | 3 | 11 |
| 1200 | 1 | 7 | 748 1981 DERMATOLOGICA 163(2):145-150 SHESKIN J; GORODETSKY R; WEINREB A; LOEWINGER E IRON CONTENT OF SKIN BEFORE AND AFTER THALIDOMIDE TREATMENT OF LEPRA REACTION - A PRELIMINARY-REPORT | 0 | 5 |
Page 4: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22